Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma

NCT05846750 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

59

Enrollment

OTHER

Sponsor class

Conditions

Marginal Zone Lymphoma

Interventions

DRUG: Obinutuzumab
DRUG: lenalidomide

Sponsor

Institute of Hematology & Blood Diseases Hospital, China